Clinical trial
Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer
NCT00088010 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00088010 |
|---|---|
| Title | Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer |
| Official title | Effects of Arzoxifene on Vertebral Fracture Incidence and on Invasive Breast Cancer Incidence in Postmenopausal Women With Osteoporosis or With Low Bone Density. |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoporosis, Postmenopausal |
| Intervention type | Drug |
| Interventions | Arzoxifene, Placebo |
| Enrollment | 9,369 |
| Start date | Jun 1, 2004 |
| Primary completion | Jun 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Jul 20, 2004 |
| Last update posted | Jun 2, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: